Market Overview

DaVita, Fresenius Medical Care Announce Partnership

Share:
Related DVA
US Stock Futures Tumble, China's Shanghai Plunges 8.5%
DaVita HealthCare Partners to Acquire Renal Ventures for $415M
Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2015 Update (Seeking Alpha)
Related FMS
Top Performing Industries For May 28, 2015
Top 4 NYSE Stocks In The Specialized Health Services Industry With The Highest Profit Margin

DaVita®, the kidney care division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced an agreement to provide certain pharmacy services to Fresenius Medical Care (FMC).

FMC, a leading provider of dialysis services and maker of dialysis products, will use DaVita Rx® prescription drug services for its Medicare patients in the United States.

Congress required that beginning in 2011, some oral medications will be included in the bundled payment model. By 2016 all oral end stage renal disease medications will be included in the bundled payment. FMC's contract with DaVita Rx will help implement that requirement by using DaVita Rx's state-of–the-art pharmacy to fill and ship oral medications to FMC Medicare patients. DaVita Rx service for FMC will begin in late 2013.

Posted-In: News Contracts

 

Related Articles (DVA + FMS)

Get Benzinga's Newsletters